Opus Genetics, Inc.
IRD
$3.61
-$0.11-2.96%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.86M | 11.98M | 14.20M | 14.63M | 15.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.86M | 11.98M | 14.20M | 14.63M | 15.42M |
| Cost of Revenue | 38.42M | 33.24M | 30.61M | 27.22M | 29.79M |
| Gross Profit | -28.57M | -21.25M | -16.42M | -12.59M | -14.37M |
| SG&A Expenses | 22.04M | 21.78M | 22.18M | 24.59M | 22.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.46M | 55.02M | 52.80M | 51.81M | 52.29M |
| Operating Income | -50.61M | -43.03M | -38.60M | -37.18M | -36.87M |
| Income Before Tax | -107.61M | -106.93M | -49.59M | -68.20M | -58.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -107.61 | -106.93 | -49.59 | -68.20 | -58.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.61M | -106.93M | -49.59M | -68.20M | -58.28M |
| EBIT | -50.61M | -43.03M | -38.60M | -37.18M | -36.87M |
| EBITDA | -50.56M | -42.98M | -38.55M | -37.13M | -36.84M |
| EPS Basic | -1.29 | -1.32 | -0.81 | -1.76 | -1.80 |
| Normalized Basic EPS | -0.81 | -0.83 | -0.51 | -0.53 | -0.55 |
| EPS Diluted | -1.35 | -1.33 | -0.81 | -1.77 | -1.81 |
| Normalized Diluted EPS | -0.80 | -0.83 | -0.51 | -0.53 | -0.55 |
| Average Basic Shares Outstanding | 333.60M | 301.49M | 248.48M | 198.26M | 153.77M |
| Average Diluted Shares Outstanding | 349.50M | 301.49M | 248.48M | 198.26M | 153.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |